Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 7;8(1):00706-2021.
doi: 10.1183/23120541.00706-2021. eCollection 2022 Jan.

SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae

Tamara Cruz  1   2 , Núria Mendoza  1 , Lídia Perea  1   2 , Núria Albacar  1   2   3 , Azucena Gonzalez  4 , Fernanda Hernandez-Gonzalez  1   2   3 , Manel Juan  4 , Alvar Agustí  1   2   3 , Jacobo Sellares  1   2   3 , Oriol Sibila  1   2   3   5 , Rosa Faner  1   2   3   5
Affiliations

SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae

Tamara Cruz et al. ERJ Open Res. .

Abstract

A specific T-cell response persists in the majority of COVID-19 patients 6 months after hospital discharge. This response is more prominent in those who required critical care during the acute COVID-19 episode but is reduced in patients with lung sequelae. https://bit.ly/3fBuVA4.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T. Cruz has nothing to disclose. Conflict of interest: N. Mendoza has nothing to disclose. Conflict of interest: L. Perea has nothing to disclose. Conflict of interest: N. Albacar has nothing to disclose. Conflict of interest: A. Gonzalez has nothing to disclose. Conflict of interest: F. Hernandez-Gonzalez has nothing to disclose. Conflict of interest: M. Juan declares research funding unrelated to the present work from ISC-III, the Spanish National health Service and Fundació La Caixa, in the 36 months prior to manuscript submission. Conflict of interest: A. Agustí has nothing to disclose. Conflict of interest: J. Sellares has nothing to disclose. Conflict of interest: O. Sibila reports funding to their institution from Menarini, Fons Mecenatge HCB-IDIBAPS, SEPAR and AGAUR (PANDEMIES 2020), in support of the present study. Conflict of interest: R. Faner declares research grants unrelated to the present work from GlaxoSmithKline LLC, Menarini, AstraZeneca, ISC-III and the Spanish National Health Service; consulting fees from GlaxoSmithKline; and payment or honoraria from Chiesi, all in the 36 months prior to manuscript submission.

References

    1. Guan WJ, Ni ZY, Hu Y, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720. doi:10.1056/NEJMoa2002032 - DOI - PMC - PubMed
    1. Sa Ribero M, Jouvenet N, Dreux M, et al. . Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog 2020; 16: e1008737. doi:10.1371/journal.ppat.1008737 - DOI - PMC - PubMed
    1. Diao B, Wang C, Tan Y, et al. . Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 2020; 11: 827. doi:10.3389/fimmu.2020.00827 - DOI - PMC - PubMed
    1. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020; 20: 269–270. doi:10.1038/s41577-020-0308-3 - DOI - PMC - PubMed
    1. Peng Y, Mentzer AJ, Liu G, et al. . Broad and strong memory CD4+ and CD8+T-cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 2020; 21: 1336–1345. doi:10.1038/s41590-020-0782-6 - DOI - PMC - PubMed